Literature DB >> 28577043

Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.

Chen Tian1, Hongliang Yang2, Lei Zhu2, Qing Zhang2, Zeng Cao2, Yizhuo Zhang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28577043     DOI： 10.1007/s00277-017-3029-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

1.  Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Authors:  Andrea Schmidts; Maria Ormhøj; Bryan D Choi; Allison O Taylor; Amanda A Bouffard; Irene Scarfò; Rebecca C Larson; Matthew J Frigault; Kathleen Gallagher; Ana P Castano; Lauren S Riley; Maria L Cabral; Angela C Boroughs; Rubí M-H Velasco Cárdenas; Wolfgang Schamel; Jing Zhou; Sean Mackay; Yu-Tzu Tai; Kenneth C Anderson; Marcela V Maus
Journal:  Blood Adv       Date:  2019-11-12

2.  Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma

Authors:  Arzu Cengiz; Hayri Üstün Arda; Firuzan Döğer; İrfan Yavaşoğlu; Yakup Yürekli; Ali Zahit Bolaman
Journal:  Turk J Haematol       Date:  2018-05-28       Impact factor: 1.831

3.  A novel luciferase-based assay for the detection of Chimeric Antigen Receptors.

Authors:  Ramakrishnan Gopalakrishnan; Hittu Matta; Sunju Choi; Venkatesh Natarajan; Ruben Prins; Songjie Gong; Arta Zenunovic; Nell Narasappa; Fatima Patel; Rekha Prakash; Vishan Chaudhary; Varun Sikri; Saurabh Deepak Chitnis; Andrei Kochegarov; Dan Wang; Magdalena Falat; Michael Kahn; Pooja Smruthi Keerthipati; Naman Sharma; Jyotirmayee Lenka; Tomas Meza Stieben; Jason Braun; Ankita Batra; Katelyn Purvis; Kenta Ito; Jae Han Lee; Alberto Jeronimo; Hannalei Mae Zamora; Allen Membreno; Queenie Qiu; Supriya Peshin; Lalith Namburu; Preet M Chaudhary
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

4.  High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.

Authors:  Yuanyan Tang; Haisen Yin; Xinying Zhao; Dan Jin; Yan Liang; Tao Xiong; Lu Li; Wen Tang; Jiangzhao Zhang; Min Liu; Zhuojun Yu; Huimin Liu; Sibin Zang; Zhiping Huang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-03

Review 5.  Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.

Authors:  Shih-Feng Cho; Lijie Xing; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

Review 6.  Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.

Authors:  Ke Liu; Jia-Jia Cui; Yan Zhan; Qian-Ying Ouyang; Qi-Si Lu; Dong-Hua Yang; Xiang-Ping Li; Ji-Ye Yin
Journal:  Mol Cancer       Date:  2022-04-11       Impact factor: 27.401

Review 7.  Clinical development of CAR T cell therapy in China: 2020 update.

Authors:  Jianshu Wei; Yelei Guo; Yao Wang; Zhiqiang Wu; Jian Bo; Bin Zhang; Jun Zhu; Weidong Han
Journal:  Cell Mol Immunol       Date:  2020-09-30       Impact factor: 11.530

Review 8.  Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.

Authors:  Marijke Timmers; Gils Roex; Yuedi Wang; Diana Campillo-Davo; Viggo F I Van Tendeloo; Yiwei Chu; Zwi N Berneman; Feifei Luo; Heleen H Van Acker; Sébastien Anguille
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.